How to Get a Step Therapy Override for GLP-1 Medications

Your doctor prescribed a GLP-1 medication like Ozempic, Mounjaro, or Wegovy, but your insurer says you must try cheaper drugs first. This "step therapy" requirement delays effective treatment while you cycle through medications your doctor did not recommend. Here is how to get an override.

Typical GLP-1 Step Therapy Requirements

Most insurers require one or more of these steps before approving a GLP-1:

1. Metformin: Nearly universal first-line requirement for type 2 diabetes. Typically 90 days at maximum tolerated dose.
2. Sulfonylurea or SGLT2 inhibitor: Some plans require a second oral agent trial, typically 90 days.
3. Older GLP-1 (Trulicity, Victoza): Some plans require trying a cheaper GLP-1 before approving Ozempic or Mounjaro.
4. Insulin: A few aggressive plans require an insulin trial before GLP-1 approval.

Five Grounds for a Step Therapy Override

1. Prior Treatment History

If you tried the required step medications before, even under a different insurance plan, you should not have to repeat them. Gather pharmacy records and medical notes documenting prior trials. Include the medication name, dosage, dates, and reason for discontinuation (inadequate efficacy, side effects, or contraindication).

2. Contraindication to Step Medication

Some patients cannot safely take the required step medication. For example, metformin is contraindicated in patients with significant renal impairment (eGFR below 30), chronic liver disease, or a history of lactic acidosis. Document the specific contraindication with lab results or clinical records.

3. Cardiovascular Risk Reduction

The ADA Standards of Medical Care recommend GLP-1 receptor agonists as a first or second-line agent (not a last resort) for patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. The SUSTAIN-6 trial showed semaglutide reduced major adverse cardiovascular events by 26%. If your patient has CVD risk factors, this clinical evidence supports bypassing step therapy.

4. Formulary Change or Plan Switch

If you were previously stable on a GLP-1 medication and your insurer changed its formulary or you switched plans, you should not be forced to restart step therapy. Many state step therapy reform laws specifically address this "continuity of care" scenario.

5. Irreversible Harm from Delay

If delaying GLP-1 treatment poses a risk of irreversible harm (such as progressive diabetic complications, worsening cardiovascular disease, or diabetic kidney disease), this is grounds for an exception. Document the clinical urgency with current lab values and imaging.

How to Submit the Override Request

• Ask your doctor's office to submit a formulary exception or step therapy override request (not a standard prior authorization)
• Include a physician letter citing the specific override grounds and supporting evidence
• Attach pharmacy records showing prior medication trials
• Reference your state's step therapy reform law if applicable
• Request expedited review if the clinical situation is urgent